Cerus Corporation (FRA:CU2)
1.906
-0.037 (-1.90%)
At close: Jan 30, 2026
Cerus Employees
As of December 31, 2024, Cerus had 630 total employees, including 614 full-time and 16 part-time employees. The number of employees decreased by 7 or -1.10% compared to the previous year.
Employees
630
Change (1Y)
-7
Growth (1Y)
-1.10%
Revenue / Employee
€272,943
Profits / Employee
€21,875
Market Cap
376.71M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 630 | -7 | -1.10% | 614 | 16 |
| Dec 31, 2023 | 637 | -40 | -5.91% | 625 | 12 |
| Dec 31, 2022 | 677 | 33 | 5.12% | 665 | 12 |
| Dec 31, 2021 | 644 | 48 | 8.05% | 631 | 13 |
| Dec 31, 2020 | 596 | 342 | 134.65% | 588 | 8 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| SIMONA Aktiengesellschaft | 1,864 |
| FRoSTA Aktiengesellschaft | 1,760 |
| Novabase S.G.P.S. | 1,281 |
| Südwestdeutsche Salzwerke AG | 1,186 |
| centrotherm international AG | 748 |
| Wild Bunch AG | 102 |
| EUWAX Aktiengesellschaft | 84 |
| Sino AG | 24 |
Cerus News
- 9 days ago - DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT Blood System in Routine Clinical Practice - Wallstreet:Online
- 9 days ago - DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT™ Blood System in Routine Clinical Practice - Business Wire
- 10 days ago - Secure Asset Management, LLC Sells 10,000 Shares of Cerus Corp (CERS) - GuruFocus
- 20 days ago - Cerus (CERS) Reports Strong Revenue Growth Driven by INTERCEPT Fibrinogen Complex - GuruFocus
- 20 days ago - CERS Projects Revenue Growth in 2026 - GuruFocus
- 20 days ago - Cerus (CERS) Reports Significant Global Expansion of INTERCEPT Blood Components in 2025 - GuruFocus
- 20 days ago - Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook - Wallstreet:Online
- 20 days ago - Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook - Business Wire